Scott + Scott, LLC Shareholder Files Securities Action Against GlaxoSmithKline plc

Scott + Scott, LLC, which filed a securities class action lawsuit on behalf of a client shareholder against GlaxoSmithKline plc (NYSE: GSK) on or around May 12, 2005 in the United States District Court for the Eastern District of Pennsylvania, states that it is prepared to litigate the case in this GSK industry center. Those who purchased securities in Glaxo between February 4, 2001 and August 5, 2004 are members of the purported class. Able Laboratories, Inc. (NASDAQ:ABRX)of New Jersey stunned the market on Thursday when it announced that it had stopped shipment of all products. Further, Able’s CEO and Chairman Dhananjay G. Wadekar resigned and the Company withdrew financial guidance. Wadekar sold significant amounts of his own stock during the class period. Abels’s shares plunged yesterday almost 75% from $18.37 per share to $6.26 per share on127 times its daily volume. Abel stated to the Financial News that this situation would have a “material effect” on its sales goals and operating objectives. You can receive copies of the GlaxoSmithKline and/or the Abel complaints from Scott + Scott, LLC (contact information below).

The Glaxo complaint alleges that GlaxoSmithKline and certain individual officers and directors with violations of the federal securities laws (Securities Exchange Act of 1934). GSK, with its subsidiaries, is a global healthcare conglomerate engaged in all phases of the pharmaceutical and consumer health-related products industry. GlaxoSmithKline's Philadelphia Headquarters are located at One Franklin Plaza, 16th and Race Streets, Philadelphia. In an agreement dated July 27, 2004 attached as an exhibit to a government filing, it states that, “28 Governing Law This Agreement shall be deemed a contract made under, and for all purposes shall be construed in accordance with, the laws of the Commonwealth of Pennsylvania. Each of the parties submits to the exclusive jurisdiction of the Commonwealth of Pennsylvania’s courts as regards any claim or matter under this Agreement.”

You can reach attorney Neil Rothstein at e-mail protected from spam bots at 800/332-2259 or 619/233-4565. If need be, you can also reach him at 619/251-0887. Attorney Amy K. Saba can be contacted at those numbers, as well, or at e-mail protected from spam bots .

During the Class Period, it is alleged that the prices of GlaxoSmithKline's stock and ADRs were artificially inflated by defendants concealing deficiencies with the Company's selective serotonin reuptake inhibitor ("SSRI") drug, Paxil, in treating adolescent depression. On August 5, 2004, The Wall Street Journal published an article that reported that a new analysis by the FDA had confirmed the link between SSRIs (including Paxil) and suicidal tendencies in young people. The prices of GlaxoSmithKline's stock and ADRs, which were inflated during the Class Period, declined from about $55 per share to $40 per share as the falsity of defendants' statements came to light.

Scott + Scott, a Connecticut-based law firm with offices in Chagrin Falls, Ohio and San Diego, California, is a law firm with a national practice and reputation. The firm is currently litigating major securities, antitrust and employee retirement plan cases throughout the United States and represents pension funds, charities, foundations, individuals and other entities worldwide -- in both class and non-class cases. Scott + Scott dedicates itself to client communication and satisfaction. Please visit our website at www.scott-scott.com (under reconstruction) to learn more about the firm, its practice and other cases. If you wish to discuss this action with an attorney or have any questions concerning this notice, your rights or any matter within our expertise, please contact attorney Neil Rothstein or Amy K. Saba at e-mail protected from spam bots. Or by calling 800-404-7770 (EST) by 12:00 p.m. or 800-332-2259 (PST) thereafter. You can dial direct in California at 619-233-4565.

Scott + Scott, LLC is based at 108 Norwich Avenue, Colchester, CT 06415; phone: 860/537-3818; fax: 860/537-4432. This release is issued in accordance with the applicable U.S. federal law.

Related Articles

• ORBOTECH Receives Injunction in its Patent Infringement Suit against Camtek
  20 May 2005



• The Pomerantz Firm Files Securities Class Action Suit against PETCO Animal Supplies, Inc. -- PETC
  14 May 2005



• Milberg Weiss Announces The Filing Of A Class Action Suit Against BearingPoint, Inc.
  4 May 2005



• Scott + Scott, LLC has Investigated and is Filing a Lawsuit
  28 April 2005



• Scott + Scott, LLC has Investigated and is Filing a Lawsuit on Behalf of Shareholders
  24 April 2005



• Emerson Poynter LLP Files Class Action Suit against 51job Inc. On Behalf of Investors
  7 February 2005



• Chiquita lawyers suit against newspaper rejected
  30 January 2005



• Prominent South Carolina Firms File Suit in SC Train Disaster
  23 January 2005



• Class Action Suit Filed Against Taser International, Inc., Officers and Directors
  19 January 2005



• Class Action Suit Announced Against Krispy Kreme Doughnuts, Inc.
  19 January 2005



• HyperRoll Files Suit Against Hyperion
  19 January 2005



• Enterasys Networks Agrees to Settle Suit Against Cabletron Systems
  19 January 2005



• Class Action Suit Filed Against ECtel
  19 January 2005



• Universal Communication Systems File Suit Against TBS, CNN and Wolf Blitzer
  16 January 2005



• Pittsburgh Law Office Announces Class Action Suit Against Pfizer, Inc.
  11 January 2005